The reason that ZF1 and ZF2 mutations had different survival impacts on de novo AML patients might be partially explained by their difference in association with CEBPAdouble-mut, and by different oncogenic mechanisms. The gene discussed is ZNF274; the disease is acute myeloid leukemia.